Investment Rating - The report does not explicitly state an investment rating for the industry or companies discussed Core Insights - Amer Sports reported strong Q3 revenue growth of 30% year-on-year, reaching $1.756 billion, and has raised its full-year revenue growth guidance to 23-24% from the previous 20% [1] - The medical aesthetics industry is experiencing a shift towards increased concentration, with leading companies like New Oxygen and Meili Tianyuan achieving differentiated growth despite a slowdown in overall industry growth [2][17] - Retail sales in the apparel sector showed signs of recovery in October, with a year-on-year increase of 6.3%, while jewelry retail also continued to improve with a 9.6% increase [3][23] Summary by Sections Section 1: Amer Sports Performance - Amer Sports' Q3 revenue reached $1.756 billion, with a net profit of $143 million, driven by significant growth in the Americas and Asia-Pacific regions [1][12] - The company has adjusted its full-year earnings per share forecast to $0.88-0.92 from $0.77-0.82, indicating strong operational performance [1][12] Section 2: Medical Aesthetics Industry Trends - The medical aesthetics market is shifting from high-priced surgical procedures to more accessible light medical aesthetics, with a projected 10% decline in average transaction value but a 10.7% increase in consumer numbers [2][17] - New Oxygen's Q3 revenue exceeded expectations, driven by a 304.6% increase in its beauty treatment services, reaching approximately $25.8 million [18][21] - Meili Tianyuan has strategically acquired 19 franchise stores to enhance its presence in the Greater Bay Area, indicating a robust growth strategy [21] Section 3: Apparel and Jewelry Retail Recovery - October apparel retail sales increased by 6.3% year-on-year, attributed to seasonal promotions and improved consumer traffic [3][23] - Jewelry retail sales also saw a year-on-year increase of 9.6%, reflecting a recovery in consumer spending [3][23] Section 4: Investment Recommendations - Recommendations include focusing on brands like Hailan Home, which is adapting to consumer trends, and companies in the beauty sector with strong brand recognition [4][38] - The report suggests monitoring the apparel sector for potential rebounds due to low valuations and improving sales data [3][23]

Market Overview - The medical beauty sector experienced a decline of 2.01% on November 21, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the medical beauty sector showed the following performance: - Huaxi Biological (688363) closed at 48.87, down 1.81% with a trading volume of 25,700 shares and a turnover of 126 million yuan [1] - Aimeike (300896) closed at 148.00, down 1.88% with a trading volume of 29,100 shares [1] - Jinbo Biological (920982) closed at 220.01, down 4.88% with a trading volume of 11,000 shares [1] - *ST Meigu (000615) closed at 3.89, down 4.89% with a trading volume of 217,100 shares and a turnover of 85.48 million yuan [1] Capital Flow - The medical beauty sector saw a net outflow of 87.65 million yuan from main funds, while retail investors contributed a net inflow of 83.50 million yuan [1] - Detailed capital flow for key stocks includes: - *ST Meigu: Main funds net outflow of 12.38 million yuan, retail net inflow of 9.03 million yuan [2] - Huaxi Biological: Main funds net outflow of 24.09 million yuan, retail net inflow of 26.09 million yuan [2] - Jinbo Biological: Main funds net outflow of 32.71 million yuan, retail net inflow of 340,200 yuan [2] - Aimeike: Main funds net outflow of 51.18 million yuan, retail net inflow of 48.38 million yuan [2]

Group 1: Battery Industry - Better Ray has been actively involved in the solid-state battery sector for over a decade, focusing on core materials for both semi-solid and all-solid batteries [4] - The company has developed a complete material system for solid-state batteries, including high-nickel cathodes, silicon anodes, lithium metal anodes, and solid electrolytes [4] - Better Ray's solid electrolyte research encompasses three directions: oxides, polymers, and sulfides, with successful small-scale applications in semi-solid batteries [4] Group 2: Biotechnology Industry - Jinbo Bio, recognized as the "first stock in medical beauty" on the Beijing Stock Exchange, holds a leading position in the field of recombinant humanized collagen, being the only company with a Class III medical device registration certificate for this product [5] - The company has maintained its technological advantage for over four years since obtaining its first registration certificate in 2021 and plans to increase R&D investment in original innovation [5] - Jinbo Bio is conducting clinical pre-experimental research on the application potential of recombinant humanized collagen in tumor treatment, specifically for breast cancer and endometrial cancer [7] Group 3: Computing Power Industry - Parallel Technology has not established a business cooperation with DeepSeek regarding computing power services, despite the growing interest in AI large models and related technologies [8][10] - The company positions itself as a provider of computing power and operational services, serving clients in AI, high-end manufacturing, and various research-driven technology enterprises [8] - Parallel Technology is actively promoting computing power services based on domestic computing chips and has integrated various types of domestic chip resources into its platform [10]

证券代码：920982 证券简称：锦波生物 公告编号：2025-181 山西锦波生物医药股份有限公司 投资者关系活动记录表 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 投资者关系活动类别 □特定对象调研 √业绩说明会 □媒体采访 □现场参观 □新闻发布会 □分析师会议 □路演活动 □其他 二、 投资者关系活动情况 活动时间：2025 年 11 月 19 日 活动地点：山西锦波生物医药股份有限公司（以下简称"公司"）在全景网 （https://rs.p5w.net/html/176291485213286.shtml）举办本次业绩说明会。 参会单位及人员：通过网络方式参加 2025 年第三季度报告业绩说明会的投 资者。 上市公司接待人员：公司董事长、总经理杨霞女士，公司董事、副总经理、 董事会秘书唐梦华女士，公司副总经理、财务总监薛芳琴女士，公司保荐代表人 中信证券邓俊先生。 三、 投资者关系活动主要内容 问题 1：面对重组胶原蛋白行业未来可能加剧的竞争，除了先发优势，公司 认为自身最深的护城河 ...

证券之星消息，11月20日医疗美容板块较上一交易日下跌2.32%，爱美客领跌。当日上证指数报收于 3931.05，下跌0.4%。深证成指报收于12980.82，下跌0.76%。医疗美容板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 231.29 | -0.55% | 6140.7 | | 1.43 Z | | 000615 | *ST美谷 | 4.09 | -1.21% | 26.65万 | | 1.09亿 | | 688363 | 华熙生物 | 49.77 | -1.54% | 2.02万 | | 1.01亿 | | 300896 | 爱美客 | 150.84 | -3.00% | 3.16万 | | 4.81亿 | 从资金流向上来看，当日医疗美容板块主力资金净流出1.04亿元，游资资金净流入1721.0万元，散户资金 净流入8685.88万元。医疗美容板块个股资金流向见下表： | 代码 | 名称 | 主力净流入 (元) | ...

Core Viewpoint - Huaheng Biological has submitted a listing application to the Hong Kong Stock Exchange for an "A+H" dual listing, with Huatai International as the sole sponsor. The company specializes in the research, production, and sales of bio-based products, holding the largest global market share for L-alanine and L-valine as of 2024. However, it faces significant challenges including declining product prices, sharply reduced profit margins, and intensified industry competition [1][2]. Financial Performance - From 2022 to 2024, Huaheng Biological's revenue is projected to grow from 1.419 billion to 2.178 billion yuan, indicating a strong growth trend. However, net profit is expected to drop from 319 million yuan in 2022 to 185 million yuan in 2024, reflecting a year-on-year decline of 58.67%. In the first three quarters of 2025, revenue reached 2.194 billion yuan, a year-on-year increase of 42.53%, but net profit still fell by 5.1% to 159 million yuan [2][3]. - The company's gross margin has significantly decreased from 40.4% in 2023 to 24.8% in 2024, and further down to 23.5% in the first three quarters of 2025, nearly halving from its peak [2][3]. Product Pricing and Market Dynamics - The decline in profitability is attributed to a comprehensive drop in market prices across nearly all product lines. For instance, the average price of amino acid products has fallen from 18,900 yuan per ton in 2022 to 15,000 yuan per ton in the first half of 2025, a decrease of over 20%. Specifically, the price of L-alanine dropped from 35,000 yuan per ton at the beginning of 2025 to 20,000 yuan per ton by mid-year, a decline of approximately 42.86% [3][4]. Supply and Demand Changes - The market's supply-demand dynamics have shifted significantly, with many sub-markets transitioning from high growth to stagnation. For example, the compound annual growth rate for valine is expected to drop from 60.2% (2020-2024) to 8.6% (2024-2030) and further to 3.4% (2030-2035). The inositol market is projected to experience nearly stagnant growth during the same period [4][5]. - The oversupply situation is exacerbated by rapid capacity expansion driven by high previous profits, alongside a slowdown in downstream demand due to macroeconomic factors. This has led to increased price competition [4][5]. Industry Competition and Strategic Shifts - Other companies in the industry are also expanding capacity, with significant new production planned for L-valine by competitors such as Yipin Biological and Jinhai Biological, which will further intensify competition [5][6]. - In response to the fierce competition in its core business, Huaheng Biological is attempting to pivot towards high-value beauty and personal care ingredients. However, this transition faces challenges due to the importance of patent barriers, brand effects, and channel control, areas where the company currently lacks strength [6][7].

Core Insights - The medical beauty sector experienced a slight increase of 0.23% on November 19, with Ai Meike leading the gains [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Sector Performance - Ai Meike (300896) closed at 155.51, up 0.58% with a trading volume of 24,500 and a transaction value of 3.83 billion [1] - Huaxi Biological (688363) closed at 50.55, up 0.30% with a trading volume of 16,100 and a transaction value of 81.47 million [1] - Jinbo Biological (920982) closed at 232.56, down 0.97% with a trading volume of 5,813.42 and a transaction value of 136 million [1] - *ST Meigu (000615) closed at 4.14, down 3.72% with a trading volume of 402,400 and a transaction value of 1.671 billion [1] Capital Flow - The medical beauty sector saw a net inflow of 1.9441 million from institutional investors, while retail investors experienced a net outflow of 12.0117 million [1] - Detailed capital flow for individual stocks shows Ai Meike with a net inflow of 26.5772 million from institutional investors, while *ST Meigu had a significant net outflow of 24.8225 million [2]

Group 1 - The North Exchange has reached a market capitalization of 900.8 billion, with a significant improvement in liquidity and market functions over its four years of development [2][5][7] - As of November 14, 2025, the North Exchange has 282 listed companies, representing a growth of 248% compared to its inception, with a total market value increase of 212% [5][7][12] - The average daily turnover rate for the North Exchange in 2025 was 5.4%, the highest among all A-shares, with 9.5 million new accounts opened, reflecting a 1.4 times increase since its launch [2][5][7] Group 2 - The North Exchange experienced three major market rallies in 2023 and 2024, driven by different catalysts: policy-driven in the first two rounds and industry-driven in the last [2][19][20] - The North Exchange 50 Index saw increases of 55.8%, 132%, and 47.4% during these rallies, indicating varying market characteristics and participant dynamics [19][20][21] - The market's focus has shifted towards "style rotation" and "industry rotation," with significant impacts from the distribution of industries and the quality of companies within those sectors [25][26][33] Group 3 - The outlook for 2026 includes accelerated reforms, with expectations for the launch of the North Exchange 50 ETF and new stock issuance reforms, which are anticipated to enhance liquidity and stabilize volatility [2][4][12] - The expected number of new stock issuances in 2026 is around 40, with projected subscription yields of 3.75%, 3.13%, and 2.34% for different investment amounts [2][4][12] - Investment strategies for 2026 suggest focusing on technology and "anti-involution" in the first half, and consumer and manufacturing sectors in the second half, with an overall emphasis on new and recently listed stocks [2][4][12]

Investment Rating - The report maintains an "Overweight" rating for the retail industry [1] Core Insights - The 2025 Double Eleven sales period saw a total e-commerce sales of approximately 1,695 billion yuan, representing a year-on-year increase of 14.2%. The comprehensive e-commerce platforms accounted for 1,619.1 billion yuan, with a year-on-year growth of 12.3% [4][9] - Instant retail showed remarkable growth, with sales reaching 67 billion yuan during the Double Eleven period, marking a year-on-year increase of 138% [10][15] - Key product categories such as digital appliances, food and beverages, furniture, and pet products experienced significant growth, with pet sales reaching 9.2 billion yuan, up 59% year-on-year [15][16] Summary by Sections Weekly Industry Viewpoint - The Double Eleven sales period was extended, contributing to steady growth in total e-commerce sales. The sales period for 2025 was from October 7 to November 11, compared to October 14 to November 11 in 2024 [9] - Instant retail emerged as a highlight, with substantial growth compared to traditional e-commerce formats [10] Weekly Market Review - From November 10 to November 16, the Shenwan retail index increased by 4.06%, while the Shanghai Composite Index decreased by 0.18% [17] - Year-to-date performance shows the Shenwan retail index up by 8.43%, compared to a 19.06% increase in the Shanghai Composite Index [17][22] Company Valuation Table - The report includes a detailed valuation table for various companies in the retail sector, with specific metrics such as market capitalization and P/E ratios [24][25]

北交所是中小企业的"加油站"，普通人的投资"新窗口"。 11月15日，北交所迎来开市四周年。 数据显示，目前，北交所已有282家上市公司，中小企业占比近八成。开市以来，北交所上市公司累计融资超600亿元，平均每家2亿元。 截至11月14日收盘，2025年北证市场累计成交额为58948.91亿元，年内日均成交额约为280.71亿元，较2024年全年日均成交额增长逾128%。 自2021年11月15日开市以来，北交所上市公司数量和总市值都已明显增长，市场活跃度和投资者参与度持续提升，其定位于服务创新型中小企业，为中小企 业长期面临的融资瓶颈提供突破，已初步形成服务"专精特新"中小企业的"中国方案"。 今年10月9日，北交所正式启用独立的920证券代码号段，与上交所（600/688）、深交所（000/300）形成"6-0-9"三位数首码格局，强化其作为第三家交易所 的市场地位。 在2025金融街论坛年会上，北交所董事长鲁颂宾表示，将深入谋划"十五五"时期北交所、新三板市场建设思路与举措，重点从功能更加完善、基础更加稳 固、服务更加友好、生态更加开放四个维度加大工作力度，推动服务创新型中小企业主阵地建设再上新台阶。 ...